The Office of the U.S. Trade Representative has extended exclusions from the Section 301 tariffs on 99 medical-care products from China needed to address COVID-19 outbreaks.
The exclusions will be extended until November 14 to allow the USTR time to conduct a full evaluation on whether it remains appropriate to exclude the products in light of increased domestic production of certain products amidst the spread of the Delta variant. The USTR will also consider the overall impact these exclusions have on eliminating China’s unfair acts, policies, and practices related to technology transfer, intellectual property, and innovation covered in the Section 301 investigation.
The full list of covered goods is available by clicking here. The exclusions are available for any product that meets the specified HTSUS numbers and product descriptions, regardless of where the importer filed an exclusion request.
